Clinical efficacy and security of glycyrrhizic acid preparation in the treatment of anti-SARS-CoV-2 drug-induced liver injury: a protocol of systematic review and meta-analysis

• Published in: BMJ open 2021-07, Vol.11 (7), p.e051484
• Main Authors: Tian, Xia, Gan, Wenfan, Nie, Yisen, Ying, Rongtao, Tan, Yongji, Chen, Junli, Chen, Mei, Zhang, Chuantao
• Format: Article
• Language: English
• Subjects: Acids; Antiviral drugs; Chemical and Drug Induced Liver Injury - drug therapy; Chemical and Drug Induced Liver Injury - etiology; China; Coronaviruses; COVID-19; COVID-19 vaccines; Cytokines; Drugs; Global Health; Glycyrrhizic Acid; Hepatitis; Humans; infectious diseases & infestations; Liver diseases; Meta-analysis; Meta-Analysis as Topic; Pandemics; Pneumonia; Proteins; protocols & guidelines; Public health; Research Design; Retrospective Studies; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Systematic review; Systematic Reviews as Topic; Treatment Outcome; Viruses
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2021-051484

IntroductionCOVID-19 is a highly infectious acute pneumonia. Glycyrrhizic acid preparation (GAP) has been found to have hepatoprotective and antiviral effects, but there is no supporting evidence on its efficacy and security for patients with COVID-19.Methods and analysisThe systematic review methods will be defined by Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. This study will start on 1 July 2021 and end on 31 October 2021. A comprehensive electronic search will be conducted with the search of Web of Science, PubMed, Ovid web, China National Knowledge Infrastructure, Chinese Scientific and Journal Database, Wanfang Database and grey literature, and manual search will be conducted to search literature of randomised controlled trials, single-arm trials and retrospective studies about GAP in the treatment of anti-SARS-CoV-2 drug-induced liver injury from 1 December 2019 to 1 July 2021. There is no time limitations of publication and language will be restricted to Chinese and English. Retrieved studies will be independently screened by two researchers and relevant data will be extracted from studies. Interstudy heterogeneity will be assessed using the I2 statistic and explored through meta-regressions and subgroup analyses. Depending on data availability, we plan to conduct subgroup analyses by study population, geographical region and other selected clinical variables of interest. Quality assessment of the studies will be performed. Cochrane Handbook for Systematic Reviews of Interventions will be used to assess the risk of bias, and Grading of Recommendations Assessment, Development and Evaluation will be used to access the confidence in cumulative evidence.Ethics and disseminationEthical approval will not be required for no primary data of individual patients will be collected. The final report will be shared with the scientific community through publication in a peer-reviewed journal, as well as with key stakeholders, including patients, healthcare professionals and those working on COVID-19 research.PROSPERO registration numberCRD42021234647.